// App-Quantinova.ai

L06 : Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study

Researchers

Presenter

  • Maya H. Buch

Principal Investigators

  • Deepak L. Bhatt

  • Christina Charles-Schoeman

  • Jon T. Giles

  • Ted R. Mikuls

  • Gary Koch

  • Steven Ytterberg

  • Edward Nagy

  • Hyejin Jo

  • Kenneth Kwok

  • Carol A. Connell

  • Karim R. Masri

  • Arne Yndestad

Medical Centers

  • Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

  • Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Division of Rheumatology, Department of Medicine, University of California, Los Angeles, Los Angeles, United States

  • Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, New York, NY

  • Division of Rheumatology, University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE

  • Department of Biostatistics, The University of North Carolina at Chapel Hil, Chapel Hill, NC

  • Division of Hematopathology, Mayo Clinic, Rochester, MN

  • Pfizer Ltd, Tadworth, Surrey, United Kingdom,

  • Pfizer Inc, New York, NY

  • Pfizer, Groton, CT

  • Pfizer Inc, Collegeville, PA

  • Pfizer AS, Oslo, Norway

Locations

  • United Kingdom

  • United States

  • Norway

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Angiology

Disease

  • Peripheral artery disease

  • Transient Ischemic Attack

  • Transient ischemic attack

  • Rheumatoid arthritis

  • Angina

  • Congestive heart failure

  • Inflammatory Arthritis

  • Coronary Artery Disease

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02092467

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved